Madrigal Pharmaceuticals, Inc. (MDGL) stock
MDGLNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/304% above fair value
$421.99−1.97 (-0.46%)
Close on Nov 17, 2026Market cap $9.75BP/E –Yield –
Madrigal Pharmaceuticals operating margin
Operating margin is operating income as a percentage of revenue.
Madrigal Pharmaceuticals's operating margin for the twelve months ending Jun 30, 2026 was -25.1%. For fiscal 2025 it was -31.3%, against -276.4% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -31.3% | +245.1 |
| FY2024 | Dec 31, 2024 | -276.4% | +41180.1 |
| FY2012 | Dec 31, 2012 | -41456.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -15.5% | +6.7 |
| Q1 FY2026 | Mar 31, 2026 | -29.8% | +28.0 |
| Q4 FY2025 | Dec 31, 2025 | -18.6% | +46.3 |
| Q3 FY2025 | Sep 30, 2025 | -39.7% | +147.4 |
| Q2 FY2025 | Jun 30, 2025 | -22.2% | +1088.2 |
| Q1 FY2025 | Mar 31, 2025 | -57.8% | – |
| Q4 FY2024 | Dec 31, 2024 | -64.8% | – |
| Q3 FY2024 | Sep 30, 2024 | -187.1% | – |
| Q2 FY2024 | Jun 30, 2024 | -1110.4% | – |
See a number that looks wrong?